Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial

Japanese Journal of Clinical Oncology

Volumn 37, Issue 7, 2007, Pages 501-508

  Kim, Yeul Hong ^a   Yamaguchi, Kensei ^b   Bang, Yung Jue ^c   Takiuchi, Hiroya ^d   Kang, Won Ki ^e   Sato, Atsushi ^f   Kang, Yoon Koo ^g   Sakamoto, Junichi ^h   Abe, Chigusa ⁱ   Sakata, Yuh ^j  

^a Korea University College of Medicine   (South Korea)

^b SAITAMA CANCER CENTER   (Japan)

^c Seoul National University College of Medicine   (South Korea)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g University of Ulsan College of Medicine   (South Korea)

^h NAGOYA UNIVERSITY   (Japan)

ⁱ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Misawa City Hospital   (Japan)

more..

Author keywords

Cisplatin; Combination chemotherapy; Gastric cancer; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPTAPLATIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MITOMYCIN; PACLITAXEL; RANITIDINE; TS 1; UFT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; INFECTION; JAPAN; LEUKOPENIA; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SOUTH KOREA; STOMACH CANCER; STOMACH SURGERY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 34548351282     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym054     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006;12:3237-42.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
5. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
6. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-74.
7. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-5.
8. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-9.
9. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in preheated advanced gastric cancer. Anti-cancer drugs 1998;9:307-10.
10. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.
11. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991;9:1692-703.
12. Gelmon KA. Biweekly paclitaxel (Taxol) and cisplatin in breast and ovarian cancer. Semin Oncol 1994;21(Suppl 8):24-8.
13. van der Gaast A, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TA. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 1999;80:1052-7.
14. Polee MB, Verweij J, Siersema PD, Tilanus HW, Splinter TA, Stoter G, et al. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Eur J Cancer 2002;38:1495-500.
15. Yamaguchi K, Shimamura. T, Komatsu Y, Takagane A, Yoshioka T, Saitoh S, et al. Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer. Gastric Cancer 2006;9:36-43.
16. Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003;26:37-41.
17. Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, et al. A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisptatin for patients with advanced gastric cancer. Oncol Rep 2004;12:1059-64.
18. Lee KW, Im SA, Yun T, Song EK, Na I, Shin H, et al. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer. Jpn J Clin Oncol 2005;35:720-6.
19. Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, et al. Effective combination chemotherapy with pactitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002;86:1858-63.
20. Stathopoulos GP, Rigatos SK, Fountzilas G, Polyzos A, Stathopoulos JG. Paclitaxel and carboplatin in pretreated advanced gastric cancer: A phase II study. Oncol Rep 2002;9:89-92.
21. Chang HM, Kim TW, Ryu BY, Choi SJ, Park YH, Lee JS, et al. Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum. Jpn J Clin Oncol 2005;35:251-5.
22. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe-B, Puistola U, et al. Randomized trial of single agent paclitaxel given wepkly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta oncol 2002;41:418-24.
23. Seidman AD; Hudis CA, Albanell J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
24. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
25. Polee MB, Eskens FA, van der Burg ME, Splinter TA; Siersema PD, Tilanus HW, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in pptients with advanced oesophageal cancer. Br J Cancer 2002;86:669-73.
26. Mok YJ, Koo BW, Whang CW,Kim SM, Maruyama K, Sasako M, et al. Cancer of the stomach: A review of two hospitals in Korea and Japan. World J Surg 1993;17:777-82.